Driving innovation in regenerative medicine: €37.5 million grant for DRIVE-RM consortium

Macro­Gen­ics and Ab­b­Vie plan to end de­vel­op­ment of their ADAM9-tar­get­ed an­ti­body-drug con­ju­gate af­ter ear­ly tri­al da­ta dis­ap­point­ed. The Mary­land-based Macro­Gen­ics said the ADC, known as

Cel­lares, which is known for pro­duc­ing the tech­nol­o­gy used in cell ther­a­py man­u­fac­tur­ing, has raised $255 mil­lion in a Se­ries C as it aims to

While artificial intelligence (AI)-assisted detection of diabetic retinopathy has the potential to expand access to screening, few patients with diabetes have been evaluated with the